Hershman D et al., 2007-02-07: SEER-Medicare cohort of women aged 65+ treated for stage I-III breast cancer, 1991-1999, followed through 2003. It found 1.16% subsequently developed AML or MDS and that G-CSF/GM-CSF use was associated with a higher hazard of those outcomes.
Of 5510 women treated with chemotherapy, 906 (16%) received G-CSF or GM-CSF therapy, and 64 (1.16%) were subsequently diagnosed with either MDS or AML before a cancer recurrence.
Abstract (Results)
Hershman D et al., 2007-02-07: SEER-Medicare cohort of women aged 65+ treated for stage I-III breast cancer, 1991-1999, followed through 2003. It found 1.16% subsequently developed AML or MDS and that G-CSF/GM-CSF use was associated with a higher hazard of those outcomes. The JNCI breast-cancer chemotherapy/leukaemia paper the claim points to. Comparator: chemotherapy with vs without G-CSF/GM-CSF (not chemo vs no chemo). Maker: no study drug; G-CSF products are Amgen (filgrastim) and sanofi (sargramostim) – the paper tests class exposure. Funder/COI not stated in the abstract; full text not read this run. Key numbers for the verifier: 906 G-CSF users, 16 (1.77%) AML/MDS vs 48 of 4604 (1.04%) non-users; hazard ratio reported in the paper's Results, not in the excerpt quoted. PubMed record is the endpoint actually opened; publisher copy is paywalled. Study type: controlled study.
